ClinicalTrials.Veeva

Menu

Caffeine Intake Inrelation to Perioperative Analgesic Consumption

A

Ain Shams University

Status

Completed

Conditions

Caffeine
Analgesia

Treatments

Dietary Supplement: Caffeine intake in mg

Study type

Observational

Funder types

Other

Identifiers

NCT05330754
R 67/ 2022

Details and patient eligibility

About

Caffeine is the most widely consumed psychoactive drug in the world. Natural sources of caffeine include coffee, tea, and chocolate. Synthetic caffeine is also added to products to promote arousal, alertness, energy, and elevated mood.

We designed this prospective observational study to determine if caffeine consumption would influence intraoperative analgesic consumption

Full description

Caffeine is a well-known natural compound present in various plant products. Caffeine is an integral component of several daily drinks, including tea, coffee, soft drinks, and energy drinks [1]. (e consumption habits of these caffeinated drinks have facilitated the wide distribution of and dependence on caffeine. For instance, 89% of the US adult population has an average caffeine intake of 200 mg/day [2]. Among the multiple effects and side effects, caffeine also has an analgesic action and is used to reduce pain in several pharmaceutical forms as an adjuvant [1]. Several studies have reported a role for caffeine in controlling pain and suggested that caffeine may block the central processing of pain signals in the brain and enhance the body's natural pain resistance pathways [3]. In addition, Overstreet et al. found that habitual caffeine consumption diminishes pain sensitivity in a laboratory setting [4]

Enrollment

90 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients scheduled to undergo elective laparoscopic surgery

Exclusion criteria

  • Patients converted to an open surgery, postoperative complications that increased postoperative pain, and those with psychological or nervous system diseases were also excluded. Liver disease

Trial design

90 participants in 3 patient groups

Control group
Description:
No caffeine intake
Treatment:
Dietary Supplement: Caffeine intake in mg
Safe level Group
Description:
Caffeine daily intake ≤200 mg/day
Treatment:
Dietary Supplement: Caffeine intake in mg
Unsafe level group:
Description:
Caffeine daily intake \>200 mg/day
Treatment:
Dietary Supplement: Caffeine intake in mg

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems